ArticleThe Journal of clinical investigation2013
Targeting immunosuppression for cancer therapy.
Article in The Journal of clinical investigation, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed.
- Interleukin-34 and immune checkpoint inhibitors: Unified weapons against cancer.Frontiers in oncology · 2023Review
- Genetically-engineered "all-in-one" vaccine platform for cancer immunotherapy.Acta pharmaceutica Sinica. B · 2021Article
- Myeloid cell-based delivery of IFN-γ reprograms the leukemia microenvironment and induces anti-tumoral immune responses.EMBO molecular medicine · 2021Article
- Pyroptosis: a new paradigm of cell death for fighting against cancer.Journal of experimental & clinical cancer research : CR · 2021Review
- Article
- Paradoxical interaction between cancer and long-term postsepsis disorder: impairment of de novo carcinogenesis versus favoring the growth of established tumors.Journal for immunotherapy of cancer · 2020Article
- Astaxanthin Treatment Induces Maturation and Functional Change of Myeloid-Derived Suppressor Cells in Tumor-Bearing Mice.Antioxidants (Basel, Switzerland) · 2020Article
- PKCζ mediated anti-proliferative effect of C2 ceramide on neutralization of the tumor microenvironment and melanoma regression.Cancer immunology, immunotherapy : CII · 2020Article
- Cancer Immunotherapies and Humanized Mouse Drug Testing Platforms.Translational oncology · 2019Review
- MALDI Mass Spectrometry Imaging Linked with Top-Down Proteomics as a Tool to Study the Non-Small-Cell Lung Cancer Tumor Microenvironment.Methods and protocols · 2019Article
- The Intriguing History of Cancer Immunotherapy.Frontiers in immunology · 2019Review
- In vitro antibacterial and cytotoxic activity of leaf extracts of Centella asiatica (L.) Urb, Warburgia salutaris (Bertol. F.) Chiov and Curtisia dentata (Burm. F.) C.A.Sm - medicinal plants used in South Africa.BMC complementary and alternative medicine · 2018Article
- The impact of inflationary cytomegalovirus-specific memory T cells on anti-tumour immune responses in patients with cancer.Immunology · 2018Review
- Safety of Combined Treatment With Monoclonal Antibodies and Viscum album L Preparations.Integrative cancer therapies · 2018Article
- Current State of Dendritic Cell-Based Immunotherapy: Opportunities forFrontiers in immunology · 2018Review
- The IDH1 Mutation-Induced Oncometabolite, 2-Hydroxyglutarate, May Affect DNA Methylation and Expression of PD-L1 in Gliomas.Frontiers in molecular neuroscience · 2018Article
- Combination Strategies to Optimize Efficacy of Dendritic Cell-Based Immunotherapy.Frontiers in immunology · 2018Review
- The Adaptive Complexity of Cancer.BioMed research international · 2018Review
- Nanoparticulate Delivery of Cancer Cell Membrane Elicits Multiantigenic Antitumor Immunity.Advanced materials (Deerfield Beach, Fla.) · 2017Article
- RSK2 phosphorylates T-bet to attenuate colon cancer metastasis and growth.Proceedings of the National Academy of Sciences of the United States of America · 2017Article
Corrections and comments
- Comment on
Authors and funding
2 authors.
Funding
Abstract
Failing immunity has been acknowledged for its contribution to cancer development and progression. Recent clinical findings have provided payoffs for significant preclinical evaluation and refinement over the last 20 years, but many questions remain to be answered. In this issue of the JCI, Marabelle et al. describe a novel method for targeting the Tregs that infiltrate tumors, demonstrating that dampening the tumor immunosuppressive environment while activating innate antitumor immunity may be an effective approach to cancer treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.